Neuroscience
Doody RS, Pavlik V, Massman P, Rountree S, Darby E, & Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther. 2010 Feb 23; 2(1):2. [Epub ahead of print]
Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA.
ABSTRACT: INTRODUCTION: Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate to see whether it predicted performance on cognition, function and behavior over time, and to see whether it predicted survival. METHODS: We used standardized approaches to assess baseline characteristics and to estimate disease duration, and calculated the initial (pre-progression) rate in 597 AD patients followed for up to 15 years. We designated slow, intermediate and rapidly progressing groups. Using mixed effects regression analysis, we examined the predictive value of a pre-progression group for longitudinal performance on standardized measures. We used Cox survival analysis to compare survival time by progression group. RESULTS: Patients in the slow and intermediate groups maintained better performance on the cognitive (ADAScog and VSAT), global (CDR-SB) and complex activities of daily living measures (IADL) (P values < 0.001 slow versus fast; P values < 0.003 to 0.03 intermediate versus fast). Interaction terms indicated that slopes of ADAScog and PSMS change for the slow group were smaller than for the fast group, and that rates of change on the ADAScog were also slower for the intermediate group, but that CDR-SB rates increased in this group relative to the fast group. Slow progressors survived longer than fast progressors (P = 0.024). CONCLUSIONS: A simple, calculated progression rate at the initial visit gives reliable information regarding performance over time on cognition, global performance and activities of daily living. The slowest progression group also survives longer. This baseline measure should be considered in the design of long duration Alzheimer's disease clinical trials.
PMID: 20178566 [PubMed - as supplied by publisher]
- Neuropsychology Abstract Of The Day: Hippocampal Atrophy
Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease Anat Rec (Hoboken). 2011 Nov 18; Greene SJ, Killiany RJ, Abstract Atrophy within the hippocampus (HP) as measured by magnetic resonance imaging (MRI) is a...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Progression
Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression Value Health. 2011 Jul-Aug;14(5):621-30 Green C, Shearer J, Ritchie CW, Zajicek JP Abstract OBJECTIVE: To consider...
- Neuropsychology Abstract Of The Day: Donepezil, Mci, And Ad
Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL & Alzheimer's Disease Cooperative Study Group. (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121. Departments of Neurology,...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, & Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3): 191-199. OBJECTIVE: To compare volumetric...
- Donepezil, Vitamin E, And Mild Cognitive Impairment In Aging
The New England Journal of Medicine has made available on its website prepublication versions of the results of a large study relevant to aging, neuropsychological changes in aging, and the onset of dementia. It has also made available in the same format...
Neuroscience
Neuropsychology Abstract of the Day: Alzheimer's Progression Rates
Doody RS, Pavlik V, Massman P, Rountree S, Darby E, & Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther. 2010 Feb 23; 2(1):2. [Epub ahead of print]
Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA.
ABSTRACT: INTRODUCTION: Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate to see whether it predicted performance on cognition, function and behavior over time, and to see whether it predicted survival. METHODS: We used standardized approaches to assess baseline characteristics and to estimate disease duration, and calculated the initial (pre-progression) rate in 597 AD patients followed for up to 15 years. We designated slow, intermediate and rapidly progressing groups. Using mixed effects regression analysis, we examined the predictive value of a pre-progression group for longitudinal performance on standardized measures. We used Cox survival analysis to compare survival time by progression group. RESULTS: Patients in the slow and intermediate groups maintained better performance on the cognitive (ADAScog and VSAT), global (CDR-SB) and complex activities of daily living measures (IADL) (P values < 0.001 slow versus fast; P values < 0.003 to 0.03 intermediate versus fast). Interaction terms indicated that slopes of ADAScog and PSMS change for the slow group were smaller than for the fast group, and that rates of change on the ADAScog were also slower for the intermediate group, but that CDR-SB rates increased in this group relative to the fast group. Slow progressors survived longer than fast progressors (P = 0.024). CONCLUSIONS: A simple, calculated progression rate at the initial visit gives reliable information regarding performance over time on cognition, global performance and activities of daily living. The slowest progression group also survives longer. This baseline measure should be considered in the design of long duration Alzheimer's disease clinical trials.
PMID: 20178566 [PubMed - as supplied by publisher]
- Neuropsychology Abstract Of The Day: Hippocampal Atrophy
Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease Anat Rec (Hoboken). 2011 Nov 18; Greene SJ, Killiany RJ, Abstract Atrophy within the hippocampus (HP) as measured by magnetic resonance imaging (MRI) is a...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Progression
Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression Value Health. 2011 Jul-Aug;14(5):621-30 Green C, Shearer J, Ritchie CW, Zajicek JP Abstract OBJECTIVE: To consider...
- Neuropsychology Abstract Of The Day: Donepezil, Mci, And Ad
Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL & Alzheimer's Disease Cooperative Study Group. (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121. Departments of Neurology,...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, & Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3): 191-199. OBJECTIVE: To compare volumetric...
- Donepezil, Vitamin E, And Mild Cognitive Impairment In Aging
The New England Journal of Medicine has made available on its website prepublication versions of the results of a large study relevant to aging, neuropsychological changes in aging, and the onset of dementia. It has also made available in the same format...